Introduzca una acción o criptomoneda en el cuadro de búsqueda para obtener un resumen
RaQualia Pharma Inc
4579RaQualia Pharma Inc. engages in the research and development of pharmaceutical compounds worldwide. Its human products portfolio includes tegoprazan for gastroesophageal reflux disease, which is in phase 3 clinical trial in the United States; and grapiprant for cancer, which is in phase I clinical trial in China and the United States, as well as grapiprant for pain management The company also provides veterinary products, such as grapiprant for osteoarthritis in dogs; ghrelin receptor agonist to treat cancer-related anorexia/cachexia syndrome, and constipation resulting from spinal cord injury; and ELURA, a drug for the management of weight loss in cats with chronic kidney disease. In addition, it provides TRPM8 blocker for the indication of chronic pain; motilin receptor agonist to treat gastrointestinal dysmotility, including gastroparesis, functional dyspepsia, and post-operative ileus; 5-HT4 partial agonist to treat gastroparesis, functional dyspepsia, and chronic constipation; 5-HT2B antagonist to treat irritable bowel syndrome with diarrhea; EP4 antagonist, a pain management drugs for dogs; serotonin 5-HT2A and dopamine D2 receptor blocker to treat schizophrenia; EP4 antagonist to treat cancer that is in phase I clinical trial; Cyclooxygenase-2 inhibitor, which is in phase I clinical trials for the indication of pain; CB2 agonist for pain; selective sodium channel blocker for pain and itch; P2X7 receptor antagonist, which is in Phase 2 clinical trials for the target indication of chronic pain. It has a collaborative agreement with Socium Corporation and Epigeneron, Inc. The company was incorporated in 2008 and is headquartered in Nagoya, Japan. Address: Meieki Southside Square, Nagoya, Japan, 450-0003
Analytics
Precio Objetivo de WallStreet
182 848.56 JPYRelación P/E
–Rentabilidad por dividendo
–Año en curso
Año anterior
Trimestre actual
Último trimestre
Año en curso
Año anterior
Trimestre actual
Último trimestre
Cifras clave 4579
Análisis de dividendos 4579
Aumento del dividendo durante 5 años
–Crecimiento continuo
–Ratio de pago medio en 5 años
–Tendencia del payout 4579
Valoración de la acción 4579
Finanzas 4579
Realice un seguimiento de las métricas clave de cada acción en un solo lugar y sin complicaciones
Hazte premiumResultados | 2019 | Dinámica |